Masimo (NASDAQ: MASI), a leading global provider of medical
technology and hospital automation solutions, and Cleveland Clinic,
a nonprofit academic medical center, announced today the launch of
a new partnership centered around hospital-based remote patient
monitoring (RPM), including TeleCritical Care. This will include
the integration of Cleveland Clinic’s critical care (eHospital) and
non-critical care (eCMU) central patient monitoring platforms with
the Masimo Hospital Automation™ platform. The goal is to provide
tools for clinicians that offer enhanced situational awareness and
clinical decision-support for hospitalized patients, including the
critically ill.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240627320405/en/
Cleveland Clinic and Masimo (Photo:
Business Wire)
The collaboration will include joint development initiatives on
predictive analytics and AI-based algorithms for improving cardiac
care.
Cleveland Clinic’s existing critical care and non-critical care
central monitoring platform provides continuous monitoring of a
range of vital signs, including ECG, for both ICU and non-ICU
patients at more than a 2,000-bed capacity. Its hospital-based RPM
programs serve 11 hospitals, providing intensivist monitoring, 24/7
critical care nursing, and patient management. Cleveland Clinic’s
programs1 have reduced patient mortality and reduced ICU length of
stay while increasing caregiver satisfaction.2 With this
partnership, Masimo and Cleveland Clinic hope to bring these
innovations and patient benefits to other healthcare systems in the
future. The aim of the enhanced program is to increase awareness
and facilitate triage with proactive responses to changes in a
patient’s condition. This improves patient care and saves lives by
ensuring the highest risk patients are identified and receive
timely treatment while maintaining quality of care for all
patients.1,2
The Masimo Hospital Automation platform offers technologies
designed to help clinicians improve patient care at the bedside,
across the care continuum. Masimo Hospital Automation includes
monitoring and wearable technologies, high-fidelity medical device
integration, system-wide applications for surveillance and data
visualization, and novel AI capabilities that support intelligent
patient prioritization and help clinicians identify changes in
patients’ condition more efficiently.
These decision-support tools are integrated into the Masimo
Hospital Automation platform and utilize the Halo engine,
technology which identifies deterioration patterns in multiple
physiological parameters simultaneously, in real time. The Halo
tools include Halo ION®, a comprehensive, scalable, and
customizable continuous early warning score to help streamline
patient assessment and clinical workflows. As part of their work
together, Masimo and Cleveland Clinic are partnering to jointly
develop an additional Halo-based decision-support tool to support
clinicians with earlier detection of adverse events – ultimately
helping them manage and improve patient outcomes more effectively,
for low-, mid-, and high-acuity patients.
“We see great opportunities to enhance remote care, particularly
for critically ill individuals,” said Chiedozie Udeh, M.D., Medical
Director of ICU Operations at Cleveland Clinic. “By combining our
technical and clinical expertise, we aim to improve situational
awareness for clinicians and continue to improve outcomes for
patients.”
Thomas Callahan, M.D., Staff Cardiologist at Cleveland Clinic’s
Heart, Vascular & Thoracic Institute, and principal
investigator for the AI study, added, “We look forward to exploring
the effects of next-gen inpatient wearables, and as the
capabilities of AI continue to advance, studying the potential
impact on the care of cardiac patients, including those undergoing
cardiac surgery.”
Joe Kiani, Founder and CEO of Masimo, said, “We are truly
honored to have the opportunity to partner with Cleveland Clinic to
advance patient care. By harnessing Masimo’s AI-powered decision
support tools, automation solutions, and monitoring devices,
alongside Cleveland Clinic’s vast clinical expertise and dedication
to providing the highest quality, most innovative care, our
partnership has the potential to significantly ease staff
shortages, better standardize care, and promote intensivist- and
specialist-led care. Ultimately, we will make significant strides
in shifting from reactive to predictive and proactive care –
improving patient outcomes, safety, and quality of care across the
board.”
Dr. Chiedozie Udeh has a conflict of interest with Cleveland
Clinic’s eHospital platform and may benefit from commercialization
of eHospital technology developed by the Company. These financial
interests are being managed by Cleveland Clinic and are within
permissible limits established by the Institutional Conflicts of
Interest Policy. eHospital is not a Masimo product.
@Masimo | #Masimo
About Masimo
Masimo (NASDAQ: MASI) is a global medical technology company
that develops and produces a wide array of industry-leading
monitoring technologies, including innovative measurements,
sensors, patient monitors, and automation and connectivity
solutions. In addition, Masimo Consumer Audio is home to eight
legendary audio brands, including Bowers & Wilkins, Denon,
Marantz, and Polk Audio. Our mission is to improve life, improve
patient outcomes, and reduce the cost of care. Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry,
introduced in 1995, has been shown in over 100 independent and
objective studies to outperform other pulse oximetry technologies.3
Masimo SET® has also been shown to help clinicians reduce severe
retinopathy of prematurity in neonates,4 improve CCHD screening in
newborns,5 and, when used for continuous monitoring with Masimo
Patient SafetyNet™ in post-surgical wards, reduce rapid response
team activations, ICU transfers, and costs.6-9 Masimo SET® is
estimated to be used on more than 200 million patients in leading
hospitals and other healthcare settings around the world,10 and is
the primary pulse oximetry at all 10 top U.S. hospitals as ranked
in the 2024 Newsweek World’s Best Hospitals listing.11 In 2005,
Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing
noninvasive and continuous monitoring of blood constituents that
previously could only be measured invasively, including total
hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin
(SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®),
RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013,
Masimo introduced the Root® Patient Monitoring and Connectivity
Platform, built from the ground up to be as flexible and expandable
as possible to facilitate the addition of other Masimo and
third-party monitoring technologies; key Masimo additions include
Next Generation SedLine® Brain Function Monitoring, O3® Regional
Oximetry, and ISA™ Capnography with NomoLine® sampling lines.
Masimo’s family of continuous and spot-check monitoring Pulse
CO-Oximeters® includes devices designed for use in a variety of
clinical and non-clinical scenarios, including tetherless, wearable
technology, such as Radius-7®, Radius PPG®, and Radius VSM™,
portable devices like Rad-67®, fingertip pulse oximeters like
MightySat® Rx, and devices available for use both in the hospital
and at home, such as Rad-97® and the Masimo W1® Medical Watch.
Masimo hospital and home automation and connectivity solutions are
centered around the Masimo Hospital Automation™ platform, and
include Iris® Gateway, iSirona™, Patient SafetyNet, Replica®, Halo
ION®, UniView®, UniView :60™, and Masimo SafetyNet®. Its growing
portfolio of health and wellness solutions includes Radius Tº® and
Masimo W1 Sport. Additional information about Masimo and its
products may be found at www.masimo.com. Published clinical studies
on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
RPVi has not received FDA 510(k) clearance and is not available
for sale in the United States. The use of the trademark Patient
SafetyNet is under license from University HealthSystem
Consortium.
References
- Cantillon et al JAMA 15-10101. Issued August 2016.
- Udeh C, Canfield C, Brown A et al. ICU Telemedicine and
Clinical Factors Related to 30-Day Mortality: A Retrospective
Cohort Study, Critical Care Medicine. January 2021 - Volume 49 -
Issue 1 - p 9 doi: 10.1097/01.ccm.0000726092.34718.60.
- Published clinical studies on pulse oximetry and the benefits
of Masimo SET® can be found on our website at
http://www.masimo.com. Comparative studies include independent and
objective studies which are comprised of abstracts presented at
scientific meetings and peer-reviewed journal articles.
- Castillo A et al. Prevention of Retinopathy of Prematurity in
Preterm Infants through Changes in Clinical Practice and SpO2
Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on
the detection of duct dependent congenital heart disease: a Swedish
prospective screening study in 39,821 newborns. BMJ. 2009;Jan
8;338.
- Taenzer A et al. Impact of pulse oximetry surveillance on
rescue events and intensive care unit transfers: a before-and-after
concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth
Experience. Anesthesia Patient Safety Foundation Newsletter.
Spring-Summer 2012.
- McGrath S et al. Surveillance Monitoring Management for General
Care Units: Strategy, Design, and Implementation. The Joint
Commission Journal on Quality and Patient Safety. 2016
Jul;42(7):293-302.
- McGrath S et al. Inpatient Respiratory Arrest Associated With
Sedative and Analgesic Medications: Impact of Continuous Monitoring
on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14
Mar. DOI: 10.1097/PTS.0000000000000696.
- Estimate: Masimo data on file.
-
https://www.newsweek.com/rankings/worlds-best-hospitals-2024/united-states
Forward-Looking Statements
This press release includes forward-looking statements as
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, in connection with the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo Hospital
Automation™, Halo, and Halo ION®. These forward-looking statements
are based on current expectations about future events affecting us
and are subject to risks and uncertainties, all of which are
difficult to predict and many of which are beyond our control and
could cause our actual results to differ materially and adversely
from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo's unique
noninvasive measurement technologies, including Hospital
Automation, Halo, and Halo ION, contribute to positive clinical
outcomes and patient safety; risks related to our belief that
Masimo noninvasive medical breakthroughs provide cost-effective
solutions and unique advantages; risks that Masimo may not realize
the expected benefits and goals that may be achieved by its
collaboration with Cleveland Clinic; risks that Masimo and
Cleveland Clinic fail to collaborate in the areas stated in this
press release as planned; risks related to COVID-19; as well as
other factors discussed in the "Risk Factors" section of our most
recent reports filed with the Securities and Exchange Commission
("SEC"), which may be obtained for free at the SEC's website at
www.sec.gov. Although we believe that the expectations reflected in
our forward-looking statements are reasonable, we do not know
whether our expectations will prove correct. All forward-looking
statements included in this press release are expressly qualified
in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of today's date. We do not
undertake any obligation to update, amend or clarify these
statements or the "Risk Factors" contained in our most recent
reports filed with the SEC, whether as a result of new information,
future events or otherwise, except as may be required under the
applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627320405/en/
Media Contacts: Masimo Evan Lamb 949-396-3376
elamb@masimo.com
Cleveland Clinic Andrea Pacetti 216-316-3040 Pacetta@ccf.org
Alicia Reale-Cooney 216-408-7444 Realeca@ccf.org
Masimo (NASDAQ:MASI)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
Von Sep 2023 bis Sep 2024